Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530946 | 0.95 | CHKA (0.51) | CHKAMAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL2534691 | 0.88 | CHKA (0.60) | CHKAMAPTTP53LMNAMEN1 | |
| SCHEMBL2530997 | 0.87 | CHKA (0.53) | CHKAMAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL2531979 | 0.86 | CHKA (0.52) | CHKAMAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL2529713 | 0.86 | SMN1; SMN2 (0.48) | CHKAMAPTTP53SMN1; SMN2ENPP1 | |
| SCHEMBL2536349 | 0.84 | TP53 (0.41) | CHKAMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL2529715 | 0.84 | MAPT (0.44) | CHKAMAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL2531303 | 0.82 | CHKA (0.54) | CHKAMAPTTP53LMNAPOLB | |
| SCHEMBL2533227 | 0.82 | SMN1; SMN2 (0.46) | MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL2534523 | 0.81 | CHKA (0.68) | CHKAMAPTTP53LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | CHKA, CHKB, CEPT1 | CHKA 1/4885MAPT 1448/4885TP53 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.